Search Results - "Au, Heather J"

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group by Moore, Malcolm J, Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R, Gallinger, Steven, Au, Heather J, Murawa, Pawel, Walde, David, Wolff, Robert A, Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy

“…Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996…”
Get full text

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group by Moore, Malcolm J, Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R, Gallinger, Steven, Au, Heather J, Murawa, Pawel, Walde, David, Wolff, Robert A, Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy

“…Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996…”
Get full text

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium by Mackay, Helen J., Au, Heather J., McWhirter, Elaine, Alcindor, Thierry, Jarvi, Andrea, MacAlpine, Katrina, Wang, Lisa, Wright, John J., Oza, Amit M.

“…Summary Purpose The Src family of kinases may play a role in the development and progression of gastric cancer. We evaluated the activity and safety of…”
Get full text

A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries by Bovier, Patrick A, Wyss, Kaspar, J. Au, Heather

“…This analysis evaluates the cost-effectiveness (C/E) of routine vaccination against Neisseria meningitidis. Three different preventive strategies are analyzed:…”
Get full text